Cargando…

Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young

OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extend...

Descripción completa

Detalles Bibliográficos
Autores principales: Thanabalasingham, Gaya, Pal, Aparna, Selwood, Mary P., Dudley, Christina, Fisher, Karen, Bingley, Polly J., Ellard, Sian, Farmer, Andrew J., McCarthy, Mark I., Owen, Katharine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357216/
https://www.ncbi.nlm.nih.gov/pubmed/22432108
http://dx.doi.org/10.2337/dc11-1243
_version_ 1782233638237110272
author Thanabalasingham, Gaya
Pal, Aparna
Selwood, Mary P.
Dudley, Christina
Fisher, Karen
Bingley, Polly J.
Ellard, Sian
Farmer, Andrew J.
McCarthy, Mark I.
Owen, Katharine R.
author_facet Thanabalasingham, Gaya
Pal, Aparna
Selwood, Mary P.
Dudley, Christina
Fisher, Karen
Bingley, Polly J.
Ellard, Sian
Farmer, Andrew J.
McCarthy, Mark I.
Owen, Katharine R.
author_sort Thanabalasingham, Gaya
collection PubMed
description OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extending genetic testing beyond current guidelines. RESEARCH DESIGN AND METHODS: Individuals were selected for diagnostic sequencing if they displayed features atypical for their diagnostic label. From 247 case subjects with clinically labeled type 1 diabetes, we sequenced hepatocyte nuclear factor 1 α (HNF1A) and hepatocyte nuclear factor 4 α (HNF4A) in 20 with residual β-cell function ≥3 years from diagnosis (random or glucagon-stimulated C-peptide ≥0.2 nmol/L). From 322 with clinically labeled type 2 diabetes, we sequenced HNF1A and HNF4A in 80 with diabetes diagnosed ≤30 years and/or diabetes diagnosed ≤45 years without metabolic syndrome. We also sequenced the glucokinase (GCK) in 40 subjects with mild fasting hyperglycemia. RESULTS: In the type 1 diabetic group, two HNF1A mutations were found (0.8% prevalence). In type 2 diabetic subjects, 10 HNF1A, two HNF4A, and one GCK mutation were identified (4.0%). Only 47% of MODY case subjects identified met current guidelines for diagnostic sequencing. Follow-up revealed a further 12 mutation carriers among relatives. Twenty-seven percent of newly identified MODY subjects changed treatment, all with improved glycemic control (HbA(1c) 8.8 vs. 7.3% at 3 months; P = 0.02). CONCLUSIONS: The systematic use of widened diagnostic testing criteria doubled the numbers of MODY case subjects identified compared with current clinical practice. The yield was greatest in young adult-onset type 2 diabetes. We recommend that all patients diagnosed before age 30 and with presence of C-peptide at 3 years' duration are considered for molecular diagnostic analysis.
format Online
Article
Text
id pubmed-3357216
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-33572162013-06-01 Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young Thanabalasingham, Gaya Pal, Aparna Selwood, Mary P. Dudley, Christina Fisher, Karen Bingley, Polly J. Ellard, Sian Farmer, Andrew J. McCarthy, Mark I. Owen, Katharine R. Diabetes Care Original Research OBJECTIVE: Misdiagnosis of maturity-onset diabetes of the young (MODY) remains widespread, despite the benefits of optimized management. This cross-sectional study examined diagnostic misclassification of MODY in subjects with clinically labeled young adult-onset type 1 and type 2 diabetes by extending genetic testing beyond current guidelines. RESEARCH DESIGN AND METHODS: Individuals were selected for diagnostic sequencing if they displayed features atypical for their diagnostic label. From 247 case subjects with clinically labeled type 1 diabetes, we sequenced hepatocyte nuclear factor 1 α (HNF1A) and hepatocyte nuclear factor 4 α (HNF4A) in 20 with residual β-cell function ≥3 years from diagnosis (random or glucagon-stimulated C-peptide ≥0.2 nmol/L). From 322 with clinically labeled type 2 diabetes, we sequenced HNF1A and HNF4A in 80 with diabetes diagnosed ≤30 years and/or diabetes diagnosed ≤45 years without metabolic syndrome. We also sequenced the glucokinase (GCK) in 40 subjects with mild fasting hyperglycemia. RESULTS: In the type 1 diabetic group, two HNF1A mutations were found (0.8% prevalence). In type 2 diabetic subjects, 10 HNF1A, two HNF4A, and one GCK mutation were identified (4.0%). Only 47% of MODY case subjects identified met current guidelines for diagnostic sequencing. Follow-up revealed a further 12 mutation carriers among relatives. Twenty-seven percent of newly identified MODY subjects changed treatment, all with improved glycemic control (HbA(1c) 8.8 vs. 7.3% at 3 months; P = 0.02). CONCLUSIONS: The systematic use of widened diagnostic testing criteria doubled the numbers of MODY case subjects identified compared with current clinical practice. The yield was greatest in young adult-onset type 2 diabetes. We recommend that all patients diagnosed before age 30 and with presence of C-peptide at 3 years' duration are considered for molecular diagnostic analysis. American Diabetes Association 2012-06 2012-05-11 /pmc/articles/PMC3357216/ /pubmed/22432108 http://dx.doi.org/10.2337/dc11-1243 Text en © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Thanabalasingham, Gaya
Pal, Aparna
Selwood, Mary P.
Dudley, Christina
Fisher, Karen
Bingley, Polly J.
Ellard, Sian
Farmer, Andrew J.
McCarthy, Mark I.
Owen, Katharine R.
Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title_full Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title_fullStr Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title_full_unstemmed Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title_short Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young
title_sort systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357216/
https://www.ncbi.nlm.nih.gov/pubmed/22432108
http://dx.doi.org/10.2337/dc11-1243
work_keys_str_mv AT thanabalasinghamgaya systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT palaparna systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT selwoodmaryp systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT dudleychristina systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT fisherkaren systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT bingleypollyj systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT ellardsian systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT farmerandrewj systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT mccarthymarki systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung
AT owenkathariner systematicassessmentofetiologyinadultswithaclinicaldiagnosisofyoungonsettype2diabetesisasuccessfulstrategyforidentifyingmaturityonsetdiabetesoftheyoung